Cargando…
A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
CD20 is a cell‐surface receptor expressed by healthy and neoplastic B cells and is a well‐established target for biologics used to treat B‐cell malignancies. Pharmacokinetic (PK) and pharmacodynamic (PD) data for the anti‐CD20/CD3 T‐cell‐dependent bispecific antibody BTCT4465A were collected in tran...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944627/ https://www.ncbi.nlm.nih.gov/pubmed/29351372 http://dx.doi.org/10.1111/cts.12535 |
_version_ | 1783321862636306432 |
---|---|
author | Ferl, Gregory Z. Reyes, Arthur Sun, Liping L. Cheu, Melissa Oldendorp, Amy Ramanujan, Saroja Stefanich, Eric G. |
author_facet | Ferl, Gregory Z. Reyes, Arthur Sun, Liping L. Cheu, Melissa Oldendorp, Amy Ramanujan, Saroja Stefanich, Eric G. |
author_sort | Ferl, Gregory Z. |
collection | PubMed |
description | CD20 is a cell‐surface receptor expressed by healthy and neoplastic B cells and is a well‐established target for biologics used to treat B‐cell malignancies. Pharmacokinetic (PK) and pharmacodynamic (PD) data for the anti‐CD20/CD3 T‐cell‐dependent bispecific antibody BTCT4465A were collected in transgenic mouse and nonhuman primate (NHP) studies. Pronounced nonlinearity in drug elimination was observed in the murine studies, and time‐varying, nonlinear PK was observed in NHPs, where three empirical drug elimination terms were identified using a mixed‐effects modeling approach: i) a constant nonsaturable linear clearance term (7 mL/day/kg); ii) a rapidly decaying time‐varying, linear clearance term (t(½) = 1.6 h); and iii) a slowly decaying time‐varying, nonlinear clearance term (t(½) = 4.8 days). The two time‐varying drug elimination terms approximately track with time scales of B‐cell depletion and T‐cell migration/expansion within the central blood compartment. The mixed‐effects NHP model was scaled to human and prospective clinical simulations were generated. |
format | Online Article Text |
id | pubmed-5944627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59446272018-05-14 A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies Ferl, Gregory Z. Reyes, Arthur Sun, Liping L. Cheu, Melissa Oldendorp, Amy Ramanujan, Saroja Stefanich, Eric G. Clin Transl Sci Research CD20 is a cell‐surface receptor expressed by healthy and neoplastic B cells and is a well‐established target for biologics used to treat B‐cell malignancies. Pharmacokinetic (PK) and pharmacodynamic (PD) data for the anti‐CD20/CD3 T‐cell‐dependent bispecific antibody BTCT4465A were collected in transgenic mouse and nonhuman primate (NHP) studies. Pronounced nonlinearity in drug elimination was observed in the murine studies, and time‐varying, nonlinear PK was observed in NHPs, where three empirical drug elimination terms were identified using a mixed‐effects modeling approach: i) a constant nonsaturable linear clearance term (7 mL/day/kg); ii) a rapidly decaying time‐varying, linear clearance term (t(½) = 1.6 h); and iii) a slowly decaying time‐varying, nonlinear clearance term (t(½) = 4.8 days). The two time‐varying drug elimination terms approximately track with time scales of B‐cell depletion and T‐cell migration/expansion within the central blood compartment. The mixed‐effects NHP model was scaled to human and prospective clinical simulations were generated. John Wiley and Sons Inc. 2018-01-19 2018-05 /pmc/articles/PMC5944627/ /pubmed/29351372 http://dx.doi.org/10.1111/cts.12535 Text en © 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Ferl, Gregory Z. Reyes, Arthur Sun, Liping L. Cheu, Melissa Oldendorp, Amy Ramanujan, Saroja Stefanich, Eric G. A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title | A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title_full | A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title_fullStr | A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title_full_unstemmed | A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title_short | A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies |
title_sort | preclinical population pharmacokinetic model for anti‐cd20/cd3 t‐cell‐dependent bispecific antibodies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944627/ https://www.ncbi.nlm.nih.gov/pubmed/29351372 http://dx.doi.org/10.1111/cts.12535 |
work_keys_str_mv | AT ferlgregoryz apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT reyesarthur apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT sunlipingl apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT cheumelissa apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT oldendorpamy apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT ramanujansaroja apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT stefanichericg apreclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT ferlgregoryz preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT reyesarthur preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT sunlipingl preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT cheumelissa preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT oldendorpamy preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT ramanujansaroja preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies AT stefanichericg preclinicalpopulationpharmacokineticmodelforanticd20cd3tcelldependentbispecificantibodies |